FTC Grants Early Termination for Servier's Tender Offer for Day One Bio
DAWN has more than doubled off its 52-week low of $5.635.
Summary
The FTC has granted early termination of the HSR waiting period, fulfilling a major regulatory condition for Servier's acquisition of Day One Biopharmaceuticals.
Key Events · M&A and Partnerships · DAWN
-
HSR Waiting Period Terminated
The Federal Trade Commission (FTC) granted early termination of the waiting period under the HSR Act on April 7, 2026, at 1:37 p.m., Eastern Time.
-
Key Acquisition Condition Met
This action satisfies a critical regulatory condition for Servier's tender offer to acquire Day One Biopharmaceuticals, moving the acquisition closer to completion.
Analysis · DAWN · Life Sciences
This amendment confirms that the Federal Trade Commission (FTC) has granted early termination of the HSR Act waiting period, effective April 7, 2026. This satisfies a key regulatory condition for Servier's tender offer to acquire Day One Biopharmaceuticals, removing a significant hurdle for the acquisition to proceed. Investors should monitor the remaining conditions for the offer's completion.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DAWN was trading at $21.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $5.64 to $21.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.